Skip to main content
Premium Trial:

Request an Annual Quote

Sequencing Technology Firm Nabsys Raises $10M in Series C Round

NEW YORK (GenomeWeb News) – DNA sequencing technology firm Nabsys today announced the closing of its Series C round, raising $10 million.

The money will be used to support continued development and commercialization of its single-molecule sequencing technology that combines electronic solid-state systems with chemistry and algorithms, the Providence, RI-based firm said. Nabsys said its systems are being developed for a broad range of applications including structural variation analysis, sequencing of targeted genes, and whole-genome sequencing.

Existing investor Stata Venture Partners led the round, which brings the total amount raised by Nabsys since April 2009 to more than $21 million. The company raised $7 million in February 2010 and $4 million in 2009.

Nabsys said that its sequencing technology will "achieve unprecedented levels of accuracy, speed, and cost … [and] reveal long-range DNA sequence information not accessible with current sequencing technologies."

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.